The Investor Relations website contains information about ALK's business for stockholders, potential investors, and financial analysts.
May. 06Alk-Abello Q1 EBIT Up At DKK 469 MlnRE Valuation: ALK-Abelló A/S Capitalization35.61BP/E ratio 2025 * 30.5x P/E ratio 2026 *26.3x Enterprise value35.55BEV / Sales 2025 * 5.73x EV / Sales 2026 *4.93x Free-Float 59.05% ...
ALK-Abelló A/S For further information please contact: Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525 Media: Maiken Riise Andersen, tel. +45 5054 1434 About ALK ALK is a global specialty pharmaceutical company focused on allergy and allerg...
ALK-Abelló A/S For further information please contact: Investor Relations: Per Plotnikof, mobile +45 2261 2525
ALK-Abelló A/S For further information please contact: Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525 Media:Maiken Riise Andersen, tel. +45 5054 1434 About ALK ALK is a global specialty pharmaceutical company ...
ALK-Abelló A/S For further information, please contact: Investor Relations: Per Plotnikof, tel. +45 2261 2525 Media: Maiken Riise Andersen, tel. +45 5054 1434 About ALK ALK is a global specialty pharmaceutical company focused on allergy and...
ALK-AbellóA/S For further information please contact: Investor Relations: Per Plotnikof, tel.+45 4574 7527, mobile +45 2261 2525 Media: Maiken Riise Andersen,tel.+45 5054 1434
The shares are traded at NASDAQ Copenhagen. ALK-Abelló A/S For further information please contact: Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525 FM_08_18UK_20032018
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) reports the following transactions: ALK-Abelló A/S For further information please contact: Investor Relations: Per Plotnikof, mobile +45 2261 2525
The final calculations have now been completed, and final allocation of share options and delivery of performance shares have taken place as stated below. ALK-Abelló A/S For further information please contact: Investor Relations: Per Plotnikof, ...